Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma.

Lattanzi M, Balar AV.

Curr Oncol Rep. 2019 Feb 26;21(3):24. doi: 10.1007/s11912-019-0775-5. Review.

PMID:
30806823
2.

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.

Lattanzi M, Deng FM, Chiriboga LA, Femia AN, Meehan SA, Iyer G, Voss MH, Sundatova Y, Huang WC, Balar AV.

J Immunother Cancer. 2018 Oct 1;6(1):97. doi: 10.1186/s40425-018-0415-x.

3.

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, Hernando E, Polsky D, Hanniford D, Shapiro R, Berman R, Pavlick AC, Wilson MA, Kirchhoff T, Weber JS, Zhong J, Osman I.

J Natl Cancer Inst. 2019 Feb 1;111(2):180-188. doi: 10.1093/jnci/djy086.

PMID:
29912415
4.

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.

Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC.

J Immunother Cancer. 2018 May 18;6(1):38. doi: 10.1186/s40425-018-0345-7.

5.

Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.

Beran J, Lattanzi M, Xie F, Moraschini L, Galgani I.

Vaccine. 2018 Feb 1. pii: S0264-410X(18)30022-7. doi: 10.1016/j.vaccine.2017.12.081. [Epub ahead of print]

6.

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.

Leroux-Roels G, Lattanzi M, Solis CD, Contorni M, Costantini M, Moraschini L, Bardelli M, Bertholet S, Borgogni E, Buricchi F, Cantisani R, Faenzi E, Finco O, Leuzzi R, Pizza M, Rosa D, Schiavetti F, Seubert A, Spensieri F, Volpini G, Zedda L, Giudice GD, Galgani I.

Hum Vaccin Immunother. 2018 Jan 2;14(1):45-58. doi: 10.1080/21645515.2017.1385686. Epub 2017 Nov 27.

7.

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.

Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.

Breast Cancer Res Treat. 2016 Aug;159(1):97-108. doi: 10.1007/s10549-016-3932-7. Epub 2016 Aug 2.

PMID:
27484880
8.

One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.

Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, Bühler S, Bosse D, Meyer S, Fragapane E, Costantini M, Pellegrini M, Lattanzi M, Dovali C.

J Travel Med. 2016 Mar 19;23(3). pii: taw011. doi: 10.1093/jtm/taw011. Print 2016 Mar.

PMID:
26994987
9.

Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.

Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, Reisinger EC, Costantini M, Gniel D, Bosse D, Lattanzi M.

Travel Med Infect Dis. 2015 May-Jun;13(3):241-50. doi: 10.1016/j.tmaid.2015.05.008. Epub 2015 May 18.

PMID:
26005163
10.

Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment.

Seripa D, Latina P, Fontana A, Gravina C, Lattanzi M, Savino M, Gallo AP, Melchionda G, Santini SA, Margaglione M, Copetti M, di Mauro L, Panza F, Greco A, Pilotto A.

Pain Med. 2015 Oct;16(10):2012-23. doi: 10.1111/pme.12778. Epub 2015 May 19.

PMID:
25989235
11.

Joint analysis of BICEP2/keck array and Planck Data.

Ade PA, Aghanim N, Ahmed Z, Aikin RW, Alexander KD, Arnaud M, Aumont J, Baccigalupi C, Banday AJ, Barkats D, Barreiro RB, Bartlett JG, Bartolo N, Battaner E, Benabed K, Benoît A, Benoit-Lévy A, Benton SJ, Bernard JP, Bersanelli M, Bielewicz P, Bischoff CA, Bock JJ, Bonaldi A, Bonavera L, Bond JR, Borrill J, Bouchet FR, Boulanger F, Brevik JA, Bucher M, Buder I, Bullock E, Burigana C, Butler RC, Buza V, Calabrese E, Cardoso JF, Catalano A, Challinor A, Chary RR, Chiang HC, Christensen PR, Colombo LP, Combet C, Connors J, Couchot F, Coulais A, Crill BP, Curto A, Cuttaia F, Danese L, Davies RD, Davis RJ, de Bernardis P, de Rosa A, de Zotti G, Delabrouille J, Delouis JM, Désert FX, Dickinson C, Diego JM, Dole H, Donzelli S, Doré O, Douspis M, Dowell CD, Duband L, Ducout A, Dunkley J, Dupac X, Dvorkin C, Efstathiou G, Elsner F, Enßlin TA, Eriksen HK, Falgarone E, Filippini JP, Finelli F, Fliescher S, Forni O, Frailis M, Fraisse AA, Franceschi E, Frejsel A, Galeotta S, Galli S, Ganga K, Ghosh T, Giard M, Gjerløw E, Golwala SR, González-Nuevo J, Górski KM, Gratton S, Gregorio A, Gruppuso A, Gudmundsson JE, Halpern M, Hansen FK, Hanson D, Harrison DL, Hasselfield M, Helou G, Henrot-Versillé S, Herranz D, Hildebrandt SR, Hilton GC, Hivon E, Hobson M, Holmes WA, Hovest W, Hristov VV, Huffenberger KM, Hui H, Hurier G, Irwin KD, Jaffe AH, Jaffe TR, Jewell J, Jones WC, Juvela M, Karakci A, Karkare KS, Kaufman JP, Keating BG, Kefeli S, Keihänen E, Kernasovskiy SA, Keskitalo R, Kisner TS, Kneissl R, Knoche J, Knox L, Kovac JM, Krachmalnicoff N, Kunz M, Kuo CL, Kurki-Suonio H, Lagache G, Lähteenmäki A, Lamarre JM, Lasenby A, Lattanzi M, Lawrence CR, Leitch EM, Leonardi R, Levrier F, Lewis A, Liguori M, Lilje PB, Linden-Vørnle M, López-Caniego M, Lubin PM, Lueker M, Macías-Pérez JF, Maffei B, Maino D, Mandolesi N, Mangilli A, Maris M, Martin PG, Martínez-González E, Masi S, Mason P, Matarrese S, Megerian KG, Meinhold PR, Melchiorri A, Mendes L, Mennella A, Migliaccio M, Mitra S, Miville-Deschênes MA, Moneti A, Montier L, Morgante G, Mortlock D, Moss A, Munshi D, Murphy JA, Naselsky P, Nati F, Natoli P, Netterfield CB, Nguyen HT, Nørgaard-Nielsen HU, Noviello F, Novikov D, Novikov I, O'Brient R, Ogburn RW, Orlando A, Pagano L, Pajot F, Paladini R, Paoletti D, Partridge B, Pasian F, Patanchon G, Pearson TJ, Perdereau O, Perotto L, Pettorino V, Piacentini F, Piat M, Pietrobon D, Plaszczynski S, Pointecouteau E, Polenta G, Ponthieu N, Pratt GW, Prunet S, Pryke C, Puget JL, Rachen JP, Reach WT, Rebolo R, Reinecke M, Remazeilles M, Renault C, Renzi A, Richter S, Ristorcelli I, Rocha G, Rossetti M, Roudier G, Rowan-Robinson M, Rubiño-Martín JA, Rusholme B, Sandri M, Santos D, Savelainen M, Savini G, Schwarz R, Scott D, Seiffert MD, Sheehy CD, Spencer LD, Staniszewski ZK, Stolyarov V, Sudiwala R, Sunyaev R, Sutton D, Suur-Uski AS, Sygnet JF, Tauber JA, Teply GP, Terenzi L, Thompson KL, Toffolatti L, Tolan JE, Tomasi M, Tristram M, Tucci M, Turner AD, Valenziano L, Valiviita J, Van Tent B, Vibert L, Vielva P, Vieregg AG, Villa F, Wade LA, Wandelt BD, Watson R, Weber AC, Wehus IK, White M, White SD, Willmert J, Wong CL, Yoon KW, Yvon D, Zacchei A, Zonca A; (BICEP2/Keck and Planck Collaborations).

Phys Rev Lett. 2015 Mar 13;114(10):101301. Epub 2015 Mar 9.

12.

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.

Knuf M, Leroux-Roels G, Rümke H, Rivera L, Pedotti P, Arora AK, Lattanzi M, Kieninger D, Cioppa GD.

Hum Vaccin Immunother. 2015;11(2):358-76. doi: 10.4161/21645515.2014.987014.

13.

mTOR inhibition improves immune function in the elderly.

Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB.

Sci Transl Med. 2014 Dec 24;6(268):268ra179. doi: 10.1126/scitranslmed.3009892.

PMID:
25540326
14.

Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Vaccine. 2015 Jan 1;33(1):174-81. doi: 10.1016/j.vaccine.2014.10.085. Epub 2014 Nov 11.

PMID:
25444803
16.

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Pediatr Infect Dis J. 2014 Dec;33(12):e320-9. doi: 10.1097/INF.0000000000000462.

PMID:
24978857
17.

A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.

Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, Lattanzi M.

Hum Vaccin Immunother. 2013 Sep;9(9):1903-9. doi: 10.4161/hv.25166. Epub 2013 Jun 19.

18.

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.

Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.

Vaccine. 2012 Jul 6;30(32):4820-7. doi: 10.1016/j.vaccine.2012.05.013. Epub 2012 May 22.

PMID:
22626675
19.

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.

Faenzi E, Zedda L, Bardelli M, Spensieri F, Borgogni E, Volpini G, Buricchi F, Pasini FL, Capecchi PL, Montanaro F, Belli R, Lattanzi M, Piccirella S, Montomoli E, Ahmed SS, Rappuoli R, Del Giudice G, Finco O, Castellino F, Galli G.

Vaccine. 2012 Jun 8;30(27):4086-94. doi: 10.1016/j.vaccine.2012.04.020. Epub 2012 Apr 19.

PMID:
22521851
20.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053. Epub 2012 Apr 1.

PMID:
22472791
21.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.

Vaccine. 2012 May 14;30(23):3470-7. doi: 10.1016/j.vaccine.2012.03.017. Epub 2012 Mar 22.

PMID:
22446638
22.

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons.

Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Casula D, Sparacio M, Kovacs C, Groth N.

Hum Vaccin Immunother. 2012 May;8(5):645-52. doi: 10.4161/hv.19493. Epub 2012 May 1.

PMID:
22418809
23.

Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.

Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.

Pediatr Infect Dis J. 2012 May;31(5):494-500. doi: 10.1097/INF.0b013e31824bb179.

PMID:
22301476
24.

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2011 Jun 1;3(85):85ra48. doi: 10.1126/scitranslmed.3002336.

25.

Supercapacitor electrodes with high-energy and power densities prepared from monolithic NiO/Ni nanocomposites.

Lu Q, Lattanzi MW, Chen Y, Kou X, Li W, Fan X, Unruh KM, Chen JG, Xiao JQ.

Angew Chem Int Ed Engl. 2011 Jul 18;50(30):6847-50. doi: 10.1002/anie.201101083. Epub 2011 May 30. No abstract available.

PMID:
21626627
26.

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S.

Clin Infect Dis. 2010 Nov 1;51(9):997-1004. doi: 10.1086/656578.

PMID:
20868284
27.

Associations of the correlates of protection and implication on the statistical power for demonstrating non-inferiority: application of a re-sampling method on a large phase III influenza vaccine clinical trial.

Bugarini R, Casula D, Groth N, Lattanzi M, Holmes S, Podda A.

Vaccine. 2010 Oct 28;28(46):7401-6. doi: 10.1016/j.vaccine.2010.08.102. Epub 2010 Sep 16.

PMID:
20850533
28.

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children.

Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Sawata H, Nakura N, Jaeger RK, Lattanzi M.

Adv Ther. 2010 Jul;27(7):444-57. doi: 10.1007/s12325-010-0043-4. Epub 2010 Jun 25.

PMID:
20586002
29.

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.

Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N.

Int J Clin Pract. 2010 Mar;64(4):432-8. doi: 10.1111/j.1742-1241.2009.02309.x. Epub 2009 Dec 17.

PMID:
20039974
30.

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.

Vaccine. 2010 Jan 8;28(3):840-8. doi: 10.1016/j.vaccine.2009.10.019. Epub 2009 Oct 14.

PMID:
19835829
31.

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A.

J Infect Dis. 2009 Sep 15;200(6):841-8. doi: 10.1086/605505. Erratum in: J Infect Dis. 2009 Dec 1;200(11):1801-2.

PMID:
19673651
32.

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.

Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M.

Vaccine. 2009 Oct 9;27(43):6022-9. doi: 10.1016/j.vaccine.2009.07.083. Epub 2009 Aug 8.

PMID:
19666152
33.

Comparison of molecular and metabolomic methods as characterization tools of Debaryomyces hansenii cheese isolates.

Del Bove M, Lattanzi M, Rellini P, Pelliccia C, Fatichenti F, Cardinali G.

Food Microbiol. 2009 Aug;26(5):453-9. doi: 10.1016/j.fm.2009.03.009. Epub 2009 Apr 2. Review.

PMID:
19465240
34.

Decaying warm dark matter and neutrino masses.

Lattanzi M, Valle JW.

Phys Rev Lett. 2007 Sep 21;99(12):121301. Epub 2007 Sep 20.

PMID:
17930494
35.

Correlation among phenotypical and molecular techniques in comparing ascomycetous yeast type strains.

De Nicola R, Corte L, Lattanzi M, Martini A, Fatichenti F, Cardinali G.

Riv Biol. 2005 Sep-Dec;98(3):449-67.

PMID:
16440281
36.

Use of RAPD and killer toxin sensitivity in Saccharomyces cerevisiae strain typing.

Corte L, Lattanzi M, Buzzini P, Bolano A, Fatichenti F, Cardinali G.

J Appl Microbiol. 2005;99(3):609-17.

37.

Long-term solutions for the problem of vaccine shortages.

Lattanzi M, Rappuoli R.

Expert Opin Biol Ther. 2004 Jun;4(6):989-92.

PMID:
15174980
38.

Fizeau interferometer for global astrometry in space.

Loreggia D, Gardiol D, Gai M, Lattanzi MG, Busonero D.

Appl Opt. 2004 Feb 1;43(4):721-8.

PMID:
14960061
39.

Exposure of bovine oocytes to the endogenous metabolite 2-methoxyestradiol during in vitro maturation inhibits early embryonic development.

Lattanzi ML, Santos CB, Mudry MD, Baranao JL.

Biol Reprod. 2003 Dec;69(6):1793-800. Epub 2003 Jul 30.

PMID:
12890717
40.

The value of vaccines.

Masignani V, Lattanzi M, Rappuoli R.

Vaccine. 2003 Jun 1;21 Suppl 2:S110-3.

PMID:
12763692
41.

Meningitis C vaccine (North American vaccine).

Lattanzi M, Del Giudice G.

Curr Opin Investig Drugs. 2002 Jan;3(1):51-3. Review.

PMID:
12054072
42.

Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance.

Cresti S, Lattanzi M, Zanchi A, Montagnani F, Pollini S, Cellesi C, Rossolini GM.

Antimicrob Agents Chemother. 2002 Jun;46(6):1816-22.

43.

Expression of 3 beta-hydroxysteroid dehydrogenase in early bovine embryo development.

Chiappe ME, Lattanzi ML, Colman-Lerner AA, Barañao JL, Saragüeta P.

Mol Reprod Dev. 2002 Feb;61(2):135-41.

PMID:
11803547
44.

Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates.

Oster P, Zanchi A, Cresti S, Lattanzi M, Montagnani F, Cellesi C, Rossolini GM.

Antimicrob Agents Chemother. 1999 Oct;43(10):2510-2.

45.

[Upper digestive hemorrhage in liver cirrhosis: clinical and endoscopic findings].

Fassio E, Viudez P, Landeira G, Fernández N, Lattanzi M, Luis A.

Acta Gastroenterol Latinoam. 1992;22(3):181-6. Spanish.

PMID:
1341118
46.

The Ryle Marital Patterns Test as a predictor of symptoms of anxiety and depression in couples in the community.

Zimmermann-Tansella C, Lattanzi M.

Soc Psychiatry Psychiatr Epidemiol. 1991 Sep;26(5):221-9.

PMID:
1745927
47.

Life events, social problems and physical health status as predictors of emotional distress in men and women in a community setting.

Zimmermann-Tansella C, Donini S, Lattanzi M, Siciliani O, Turrina C, Wilkinson G.

Psychol Med. 1991 May;21(2):505-13.

PMID:
1876655
48.

Methodology of the H2 breath test. II. Importance of the test duration in the diagnosis of carbohydrate malabsorption.

Corazza GR, Sorge M, Strocchi A, Lattanzi MC, Benati G, Gasbarrini G.

Ital J Gastroenterol. 1990 Oct;22(5):303-5.

PMID:
2134331
49.

Methodology of the H2 breath test. I. Collection and storage for gas measurement.

Corazza GR, Sorge M, Mauriño E, Strocchi A, Lattanzi MC, Gasbarrini G.

Ital J Gastroenterol. 1990 Aug;22(4):200-4.

PMID:
2131946
50.

[Value of laboratory tests and echography in the diagnosis of biliary disease in the initial phase of acute pancreatitis].

Parodi HC, Gutiérrez S, Lattanzi M, Martínez R, Colombato LO.

Acta Gastroenterol Latinoam. 1990;20(3):137-44. Spanish.

PMID:
2095097

Supplemental Content

Loading ...
Support Center